General Information of the Protein
Protein ID
PT01749
Protein Name
Diacylglycerol O-acyltransferase 2
Secondarily
Protein Name
Acyl-CoA retinol O-fatty-acyltransferase
Diglyceride acyltransferase 2
Gene Name
DGAT2
Secondarily
Gene Name
HMFN1045
UNQ738/PRO1433
Sequence
MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLNRSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKGGRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATEVSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGGAAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQKKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHTMYMEALVKLFDKHKTKFGLPETEVLEVN
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Transferase
Function
Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides (PubMed:27184406). Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT) (By similarity). Also able to use 1-monoalkylglycerol (1-MAkG) as an acyl acceptor for the synthesis of monoalkyl-monoacylglycerol (MAMAG) (PubMed:28420705).
    Show/Hide
Uniprot ID
Primary ID:
Q96PD7

Secondarily ID:
A6ND76
Q5U810
Q68CL3
Q68DJ0
Q8NDB7
Q96BS0
Q9BYE5
    Show/Hide
HGNC ID
HGNC:16940
Subcellular Location
Endoplasmic reticulum membrane
Lipid droplet
Cytoplasm
Perinuclear region
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000013 , Sf9
Compound ID Compound Name Compound Formula
CP0058071
N-tert-butyl-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-5-[3-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide
   Show/Hide
C29H32F3N5O4
 1
1
IC50 = 2 nM
   TI
   LI
   LO
   TS
CP0128442
N-tert-butyl-5-(3-methoxyphenyl)-8-[[[(1S,2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarbonyl]amino]methyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide
   Show/Hide
C29H35N5O4
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0227630
N-tert-butyl-5-(3-methoxyphenyl)-8-[[[(1R,2R)-2-phenylcyclopropanecarbonyl]amino]methyl]-3,4-dihydro-1H-isoquinoline-2-carboxamide
   Show/Hide
C32H37N3O3
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0487281
tert-butyl 5-(3-methoxyphenyl)-8-[[[(1R,2R)-2-phenylcyclopropanecarbonyl]amino]methyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate
   Show/Hide
C32H36N2O4
 1
1
IC50 = 60 nM
   TI
   LI
   LO
   TS
CP0231766
US9828369, Example 155
   Show/Hide
C25H19Cl2N3O3
 1
1
IC50 = 120 nM
   TI
   LI
   LO
   TS
CP0257873
methyl 3-[4-[[[(1R,2R)-2-phenylcyclopropanecarbonyl]amino]methyl]naphthalen-1-yl]benzoate
   Show/Hide
C29H25NO3
 1
1
IC50 = 140 nM
   TI
   LI
   LO
   TS
CP0491031
N-((5-(3-methoxyphenyl)isoquinolin- 8-yl)methyl)spiro[2.5]octane-1- carboxamide
   Show/Hide
C26H28N2O2
 1
1
IC50 = 180 nM
   TI
   LI
   LO
   TS
CP0128440
(1R,2R)-N-[[5-(3-methoxyphenyl)quinolin-8-yl]methyl]-2-phenylcyclopropane-1-carboxamide
   Show/Hide
C27H24N2O2
 1
1
IC50 = 300 nM
   TI
   LI
   LO
   TS
CP0231765
(1R,2R)-N-[5-(3-methoxyphenyl)isoquinolin-8-yl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropane-1-carboxamide
   Show/Hide
C23H20N4O3
 1
1
IC50 = 500 nM
   TI
   LI
   LO
   TS
CP0058070
1-(2,3-dichlorophenyl)-3-[[5-(3-methoxyphenyl)isoquinolin-8-yl]methyl]urea
   Show/Hide
C24H19Cl2N3O2
 1
1
IC50 = 540 nM
   TI
   LI
   LO
   TS
CP0487280
(1R,2R)-N-[[5-(3-methoxyphenyl)isoquinolin-8-yl]methyl]-2-phenylcyclopropane-1-carboxamide
   Show/Hide
C27H24N2O2
 1
1
IC50 = 600 nM
   TI
   LI
   LO
   TS
CP0538644
(1R,2R)-N-[[8-(3-methoxyphenyl)isoquinolin-5-yl]methyl]-2-phenylcyclopropane-1-carboxamide
   Show/Hide
C27H24N2O2
 1
1
IC50 = 1600 nM
   TI
   LI
   LO
   TS
CP0573605
(1R,2R)-2-phenyl-N-[[5-[3-(trifluoromethoxy)phenyl]isoquinolin-8-yl]methyl]cyclopropane-1-carboxamide
   Show/Hide
C27H21F3N2O2
 1
1
IC50 = 2200 nM
   TI
   LI
   LO
   TS
CP0265409
(1R,2R)-N-[[2-acetyl-5-(3-methoxyphenyl)-3,4-dihydro-1H-isoquinolin-8-yl]methyl]-2-phenylcyclopropane-1-carboxamide
   Show/Hide
C29H30N2O3
 1
1
IC50 = 3460 nM
   TI
   LI
   LO
   TS
CP0060386
2-[4-[4-[4-(phenylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-7-yl]phenyl]cyclohexyl]acetic acid
   Show/Hide
C29H30N2O4
 1
1
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0295271
CHEMBL3287865
   Show/Hide
C30H32N2O4
 1
1
IC50 = 10000 nM
   TI
   LI
   LO
   TS
CP0552436
1-[(5-chloroisoquinolin-8-yl)methyl]-3-(2,3-dichlorophenyl)urea
   Show/Hide
C17H12Cl3N3O
 1
1
IC50 > 12000 nM
   TI
   LI
   LO
   TS
CP0476412
2-[[5-(4-benzamidophenyl)-4-methyl-1,2,4-triazol-3-yl]sulfanyl]propanoic acid
   Show/Hide
C19H18N4O3S
 1
1
IC50 > 20000 nM
   TI
   LI
   LO
   TS
CP0115631
2-[4-[4-[1-(phenylcarbamoyl)indol-5-yl]phenyl]cyclohexyl]acetic acid
   Show/Hide
C29H28N2O3
 1
1
IC50 > 50000 nM
   TI
   LI
   LO
   TS
CP0552437
[5-(3-methoxyphenyl)isoquinolin-8-yl]methanamine
   Show/Hide
C17H16N2O
 1
1
IC50 > 50000 nM
   TI
   LI
   LO
   TS
CP0050575
4-(4-{4-[(2-Phenyl-5-trifluoromethyloxazole-4-carbonyl)-amino]phenyl}piperidine-1-carbonyl)-trans-cyclohexanecarboxylic Acid
   Show/Hide
C30H30F3N3O5
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0060386
CHEMBL3233884
   Show/Hide
C29H30N2O4
 1
1 IC50 > 10000 nM
CP0115631
CHEMBL3233872
   Show/Hide
C29H28N2O3
 1
1 IC50 > 50000 nM
Clinical Information about the Protein
Target 1 ( Diacylglycerol O-acyltransferase 2 (DGAT2) )
Target Type Successful Target
Disease 2 Target-related Diseases  2
1 Lipid metabolism disorder [ICD-11: 5C52.Z]
2 Non-alcoholic steatohepatitis [ICD-11: DB92.1]
Approved Drug(s) 1 Approved Drug  1
1 Vitamin B3 Approved
Lipid metabolism disorder
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 PF-06865571 Phase 2
Non-alcoholic steatohepatitis
Target 2 ( DGAT2 messenger RNA (DGAT2 mRNA) )
Target Type Clinical trial Target